Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03466502 · ClinicalTrials.gov registry record · Phase 4
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
A Phase 4 study of Clostridium Difficile Infection, sponsored by University of Nevada, Reno.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT03466502 is a Phase 4 study of Clostridium Difficile Infection that has completed, run by University of Nevada, Reno. The registered enrollment target is 104 participants, below the 12,058-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03466502, a Phase 4 study of Clostridium Difficile Infection, has completed, sponsored by University of Nevada, Reno.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
Conditions Studied
Interventions
- DRUG Oral Vancomycin
Study Locations (1)
Nevada
- Renown Regional Medical Center - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03466502
The ClinicalTrials.gov registry entry for NCT03466502 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,058-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The listed sponsor is University of Nevada, Reno, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 1 intervention - of which Oral Vancomycin is the first listed.
NCT03466502 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.
Frequently Asked Questions
What is clinical trial NCT03466502 about?
NCT03466502 is a clinical study titled "Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics". This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
What is the current status of trial NCT03466502?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2018-03-08. Estimated completion is 2022-02-17.
What conditions does trial NCT03466502 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection.
What interventions are being tested in trial NCT03466502?
The interventions under investigation include: Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT03466502?
This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03466502 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
RECRUITING · NA
-
Fecal Microbiota Transplantation for C Diff Infection
RECRUITING · NA
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Fecal Microbiota Transplant National Registry
RECRUITING
-
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
RECRUITING · Phase 2
-
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.